Overview of Immunotherapy for Early-Stage NSCLC and Clinical Factors Influencing Response to Checkpoint Inhibition

Download these slides from a live CCO Webinar for an overview of the evolving immunotherapy landscape for early-stage NSCLC along with coverage on how cachexia, immune-related adverse events, and disparities in care impact outcomes for patients with NSCLC receiving checkpoint inhibitor therapy.
person default
Mary Jo Fidler, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 3.30 MB
Released: June 24, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Helsinn Healthcare SA
Regeneron Pharmaceuticals, Inc.
Sanofi Genzyme

Related Content

Patient-friendly resource on immune checkpoint inhibitor therapy for early-stage NSCLC from Clinical Care Options (CCO)

Elizabeth Krueger, NP Released: September 22, 2021

Phase I trials of EGFR/HER2 inhibitor DZD9008 in patients with advanced NSCLC and EGFR ex20ins mutations, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 20, 2021

Phase II ATEZO-BRAIN evaluating atezolizumab plus carboplatin/pemetrexed in advanced NSCLC with untreated brain metastases, from WCLC2021 as reported by Clinical Care Options (CCO)

Released: September 20, 2021

Download these slides for an overview of the evolving immunotherapy landscape for advanced or metastatic NSCLC, from CCO

Julie Brahmer, MD, MSc person default Jarushka Naidoo, MB BCH BAO, MHS Released: September 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue